Search

Searching with a thematic focus on WTO, Trade Policy, Health

Showing 1-9 of 9 results

• Document

  TRIPS agreement and access to drugs in developing countries

  Sur - International Journal on Human Rights, 2005

  This article examines the progress made in the process to lend more flexibility to the TRIPS Agreement for medical drugs, and shows how the Doha Declaration and the 2003 Decision of the TRIPS Board on the implementation of its paragraph 6 are insufficient to ensure a reduction in prices and the negotiation of voluntary licenses.The paper argues that:the implementation of the Decision on
• Document

  WTO decision on implementation of paragraph 6 of the Doha Declaration on the TRIPS Agreement and Public Health: a solution to the access to essential medicines problem?

  Publishers WWW sites, 2004

  This article from the Journal of International Economic Law looks at the problem identified in paragraph 6 of the Doha Declaration on the TRIPS Agreement and Public Health – namely that of ensuring access to low-cost essential medicines in developing countries in the context of compulsory licensing provisions.
• Document

  One step forward, two steps back? Issues for the 5th WTO Ministerial Conference (Cancun 2003)

  Médecins Sans Frontières, 2003

  In order to protect global public health at Cancún, MSF asks World Trade Organization members to:Implement Doha:developing countries should implement and seize the opportunities afforded by the Doha Declaration.
• Document

  Implementing the Doha Mandate on TRIPS and Public Health

  Development Gateway, 2003

  This World Bank Trade Note reviews the state of play in the ongoing negotiations over the implementation of the Doha mandate on TRIPS and public health.
• Document

  Implications of the Doha Declaration on the TRIPS Agreement and public health

  Essential Drugs and Medicine Policy, WHO, 2002

  The special declaration on issues relating to the Agreement on Trade-Related Aspects of Intellectual Property (TRIPS) represents an unprecedented step for the World Trade Organisation (WTO), but what are its implications?
• Document

  Health (and IPRs)

  Commission on Intellectual Property Rights, 2002

  It is feared that stronger patent protection is likely to increase the costs of medicines and reduce the ability of the poorest developing countries to improve public health conditions among their populations. Yet for pharmaceutical companies, patent protection gives them incentives to conduct research and development into new drugs.
• Document

  Anthrax, Drug Transnationals, and TRIPs

  Foreign Policy in Focus, 2002

  Opinion piece from the Director of the Public Interest Research Centre in India which looks at TRIPS and the Doha declaration and draws inferences from the recent anthrax crisis in the US.Among the points the author makes are that:By sacrificing the public health concern of its own citizens to protect the private interests of drug TNCs, the U.S.
• Document

  WTO TRIPS agreement and its implications for access to medicines in developing countries

  Commission on Intellectual Property Rights, 2002

  This detailed issue briefing examines TRIPS in light of the Doha Declaration which mandates that TRIPS be interpreted in a manner that supports public health interests and promotes access to medicines.The study accepts the consensus of experts that developing countries should make use of policy options such as compulsory licensing and parallel importation to increase the supply of low-price med
• Document

  WTO ministerial declaration on the TRIPs agreement and public health: the issues at stake

  European Commission, Directorate General for Trade, 2001

  Note which sets out the Trade Directorate General's (DG III) position on the agreement on TRIPS and access to essential medecines agreed at the Doha WTO MinisterialThe paper is set out in a question and answer format which addressed the following:What is the major value of this Declaration?Why was it necessary to clarify the relationship between TRIPs and public health?What cla